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ABSTRACT—Approximately 3 billion people around the world have gone into some form of social separation to mitigate the
current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The uncontrolled influx of patients in
need of emergency care has rapidly brought several national health systems to near-collapse with deadly consequences to
those afflicted by Coronavirus Disease 2019 (COVID-19) and other critical diseases associated with COVID-19. Solid
scientific evidence regarding SARS-CoV-2/COVID-19 remains scarce; there is an urgent need to expand our understanding
of the SARS-CoV-2 pathophysiology to facilitate precise and targeted treatments. The capacity for rapid information
dissemination has emerged as a double-edged sword; the existing gap of high-quality data is frequently filled by anecdotal
reports, contradictory statements, and misinformation. This review addresses several important aspects unique to the
SARS-CoV-2/COVID-19 pandemic highlighting the most relevant knowledge gaps and existing windows-of-opportunity.
Specifically, focus is given on SARS-CoV-2 immunopathogenesis in the context of experimental therapies and preclinical
evidence and their applicability in supporting efficacious clinical trial planning. The review discusses the existing challenges
of SARS-CoV-2 diagnostics and the potential application of translational technology for epidemiological predictions, patient
monitoring, and treatment decision-making in COVID-19. Furthermore, solutions for enhancing international strategies in
translational research, cooperative networks, and regulatory partnerships are contemplated.
KEYWORDS—Acute respiratory distress syndrome, animal models, clinical trials, immuno-modulation, pandemic,
pneumonia
INTRODUCTION
In late 2019, a novel human coronavirus, termed severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged
in Wuhan, China. SARS-CoV-2 quickly spread in several
Chinese provinces producing a high incidence of acute respi-
ratory illness (1). Following its further spread, the World Health
Organization (WHO) has coined this global illness Coronavirus
Disease 2019 (COVID-19) and has declared the outbreak to be
a Public Health Emergency of International Concern on Janu-
ary 30, 2020. SARS-CoV-2 infections quickly escalated to a
pandemic with virtually all continents reporting COVID-19
cases (2). The SARS-CoV-2 infections appeared to have spread
in China over several weeks prior to the first delayed reports of
patients suffering from severe pneumonia in late December
2019. Since then, the number of confirmed cases has
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exponentially increased, first in China, subsequently across
other continents with almost five million people affected (3).
The countries currently most affected by this pandemic are the
United States (US) as well as Russia, the UK, Spain, Italy and
France in Europe, and the UK in Europe accounting for more
than 70% of the entire global death toll (3). According to the
WHO, the April spike of SARS-CoV-2 infections in Africa
positions this continent as the next epicenter with dire con-
sequences for its population. In May 2020, the US recorded the
highest number of known coronavirus cases (with new cases
continuously increasing) compared to any other country with
one-and-half million cases. However, an enormous variability
in testing and data reporting (deaths usually not confirmed
through autopsy) exist, which impedes precise estimations. The
yet known global propagation pathways of SARS-CoV-2 based
on its genetic fingerprinting are displayed in Figure 1 (4).
Given that the initial containment was often delayed and
insufficient (5, 6), the most affected countries have introduced a
range of restrictive mitigation mechanisms such as social
distancing, border closures, and travel/business restrictions.
On March 18, 2020, more than 250 million people went into
lockdown in Europe. The enormous and uncontrolled influx of
patients in need of specialized medical care has rapidly brought
several national health systems to near-collapse. Adhering to
the WHO call (7), the healthcare systems worldwide rapidly
increased hospital capacities and adapted to the specific needs
of COVID-19 patients as a fundamental response measure.
These adaptation mechanisms, however, are difficult (impossi-
ble) to achieve in many underprivileged regions/countries with
an under-developed health infrastructure putting those popu-
lations at much higher risk.
SARS-CoV-2 is assumed to be mainly spread via small
droplets produced at coughing/sneezing in close contact (up
to 2 m) although longer distances cannot be ruled out (8).
Experimental evidence shows that SARS-CoV-2 may remain
viable in aerosols up to 3 h and up to 72 h on various surfaces
such as plastic, steel, copper, and cardboard (9). Of note, the
American Centers for Disease Control and Prevention (CDC)
reported that SARS-CoV-2 RNA was identified on cabin sur-
faces of a cruise ship 17 days after cabins had been vacated; it is
unclear whether the material remained infectious (10). High
viral load and active shedding in the upper respiratory tract that
peaks during the first week of symptoms, suggests that SARS-
CoV-2 is most contagious in already symptomatic subjects
although some spread is likely before occurrence of symptoms
(11). The SARS-CoV-2 infection may be asymptomatic in
some people; analysis of the ‘‘Diamond Princess’’ cruise ship
cohort indicated that approximately 19% of the infected
FIG. 1. Phylogeny, evolutionary relationships, global propagation pathways, and timeline of SARS-CoV-2 viruses from the ongoing COVID-19
pandemic. Despite relatively clear genetic relationships among sampled viruses, an uncertainty for specific transmission dates and the reconstruction of the
geographic spread remains. Note that the specific inferred transmission patterns (connecting lines) are only hypothetical (4). Thousands of complete genomes are
available and increase on a daily basis. The visualization is based upon sub-sampled available genome data (see more under: https://nextstrain.org/ncov). As the
pathogen replicates and spreads, its genome is replicated and random mutations/errors accumulate in the genome. Such random mutations allow tracking of the
SARS-CoV-2 spread inferences regarding its transmission routes and dynamics. The colors indicate the origin/source of the various viral strains, while circle
diameters reflect the size of the transmission clusters. The initial SARS-CoV-2/COVID-19 emergence occurred in Wuhan, China, in November and December
2019, with the first (officially announced) COVID-19-related death on January 11, 2020. The phylogeny is rooted relative to early samples obtained from Wuhan,
China. Thereafter, a sustained human-to-human transmission with the first case outside of China (Thailand) was confirmed on January 13, 2020. On January 21,
2020 the first case was confirmed in North America (Wash, USA) and 4 days later in Australia (Victoria). The first three cases in Europe were reported in France on
January 24, 2020 (first death on February 15, 2020 France). COVID-19 surveillance was implemented by the European CDC and WHO in the European Region on
January 27, 2020, 3 days later the WHO declared SARS-CoV-2 a global emergency. On February 14, 2020 the first case in Africa (Egypt) was confirmed. On
February 21, 2020 nine European countries (Belgium, Finland, France, Germany, Italy, Russia, Spain, Sweden, and UK) reported SARS-CoV-2/COVID-19 cases.
On February 25, 2020 SARS-CoV-2 reached South America (São Paulo, Brazil). On March 11, 2020 the WHO declared SARS-CoV-2 a pandemic and 2 days later
Europe was announced the active pandemic center; on 17 March 2020, all European countries reported confirmed SARS-CoV-2/COVID-19 cases. On March 31,
2020 the number of COVID-19-related deaths (>3,500) in the US surpassed those (officially reported) in China. The highest worldwide daily death toll of 10,761
was recorded on April 27, 2020; as of May 18, 2020, 4,727,625 confirmed cases in 213 countries/territories and two international conveyances with 315,389
deaths were reported (www.worldometers.info). Graphic modified based on https://nextstrain.org/ncov (accessed on April 27, 2020). COVID-19 indicates
coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
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passengers remained clinically healthy (12). The viral load in
asymptomatic patients may reach a level comparable to the one
seen in symptomatic patients; preliminary evidence demon-
strates that asymptomatic patients may transmit the virus but
the transmission pathways and timing are yet to be identified
(13, 14). The percentage of patients who remain truly asymp-
tomatic for the course of their infection is unknown; it is
likewise unclear what percentage of individuals who initially
present with an asymptomatic infection subsequently progress
into clinical disease.
Clinical features of COVID-19 are nonspecific and are
hardly distinguishable from other causes of severe community
and hospital-acquired pneumonia. While approximately 80%
of cases follow a relatively mild trajectory, the elderly and/or
patients with comorbidities (e.g., chronic lung conditions,
hypertension, diabetes, and obesity) are at risk for severe
COVID-19 course with pneumonia as the typical manifestation
(Fig. 2) (15). Not infrequently, patients may show a dispropor-
tionate extent of radiographic pulmonary involvement com-
pared to the mild level of hypoxemia. Some of these patients
suddenly deteriorate to severe respiratory failure followed by
intubation and mechanical ventilation requirement. Deaths
appear to be dominated by severe respiratory failure, fulminant
myocarditis (leading to heart failure), thrombo-embolic events
(stroke, infarcts, embolism), and late secondary sepsis with
severe single or multiorgan dysfunction (typically involving the
liver and kidneys) (16–18). Renal dysfunction may be an early
sign for later deterioration. Emerging data suggest that severe
COVID-19 phenotypes are associated with a significant (hyper-
) coagulopathy that correlates with disease severity (19–21).
Direct viral infection of the endothelial cells and diffuse
endothelial inflammation with a shift of the vascular equilib-
rium toward enhanced vasoconstriction (with subsequent organ
ischemia), inflammation with an associated tissue edema, and a
pro-coagulant state may constitute the main underpinnings of
the severe clinical phenotypes (22, 23). Studies confirm the
high rate of comorbidities among deceased SARS-CoV-2/
COVID-19 patients, but serial (and better powered) studies
are needed to precisely identify the cause(s) of death in the most
severe cases (24).
With most of the world in lockdown, an ongoing SARS-CoV-2
spread and new infection waves expected, the pandemic will
continue to represent a major global threat (25). As solid scientific
evidence remains scarce, there is an urgent need to expand our
understanding of the SARS-CoV-2 evolving epidemiology, its
infectivity and body site-specific replication as well as COVID-19
immuno-inflammatory characteristics and treatment strategies
against it (25). The existing gap of high-quality, reproducible
evidence-based data is frequently filled by anecdotal reports,
contradictory statements (26), and misinformation. The present
review addresses several important aspects unique to the SARS-
CoV-2/COVID-19 pandemic highlighting the newest evidence,
most relevant knowledge gaps, and windows-of-opportunity.
COMPARISON OF COVID-19 TO THE RECENT
VIRAL PANDEMICS
COVID-19 is the fourth viral pandemic of the last two
decades following the SARS virus in 2002/2003, the influenza
A virus H1N1 in 2009, and the Middle East Respiratory
Syndrome (MERS) virus in 2012 (Table 1). All these viruses
are enveloped by a host cell-derived membrane and contain a
single RNA as genome. Many of the RNA viruses possess the
capacity to induce zoonotic infections. Wild birds are a reser-
voir for influenza A viruses that may be transmitted to swine,
human, and other mammals (27). SARS-CoVand SARS-CoV-2
have high similarity to coronaviruses (CoV) in bats and likely
have been transmitted from bats to humans via an intermediate
host (civet for SARS-CoV; possibly pangolin for SARS-CoV-2)
(28–30). MERS-CoV was transmitted from camels to humans,
with limited human-to-human transmission capacity (but high
pathogenicity; (31)). Due to the tight contact between camels
and humans, in some communities, MERS-CoV continues to
circulate and temporal disease clusters arise.
H1N1 (and other influenza viruses) belong to the Orthomyx-
oviridae and induce upper respiratory tract infections. Influ-
enza A virus enters the host via the viral hemagglutinin
attaching to sialic acid residues present on upper respiratory
tract cells with an average incubation time of 2 days (32). The
2009 pandemic H1N1 virus integrated gene segments from
FIG. 2. A pulmonary presentation of SARS-CoV-2 infection in a severely ill, intubated, and mechanically ventilated COVID-19 patient by computed
tomography (CT; panel A) and plain chest x-ray imaging (panel B). The CT shows characteristic milk-glass like opacities with consolidations in both upper
lobes (A). CT findings may be unspecific and the primary diagnosis of SARS-CoV-2 remains laboratory-based. However, if indicated, imaging studies are helpful in
assessing the severity and the course of COVID-19 pneumonia. A CT score can be used to evaluate the severity of the disease (15). The risks of an in-hospital
transfer and potential contamination need to be considered. (Source: Axel Gossmann (MD), Department of Radiology, Cologne-Merheim Medical Center
(CMMC), Cologne, Germany). COVID-19 indicates coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
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multiple avian and mammalian strains thereby forming a novel
virus unrecognizable by any pre-existing immunity (27).
Despite relatively efficient vaccines and antiviral drugs, the
flu continues to kill >200,000 people worldwide per year (33).
SARS, MERS, and the novel COVID-19 are caused by CoV
that are widely distributed, highly infectious and responsible
for the symptoms associated with common cold in humans, i.e.,
the strains NL63, OC43, 229E, and HKU1. For their entry into
the human cells, SARS-CoV and SARS-CoV-2 use a spike
protein that binds to the angiotensin-converting enzyme (ACE)
2 on alveolar type II cells in the lung (also airways mucosa)
(34). The expression of ACE2 in the liver, heart, and gastroin-
testinal tract (Table 2) may explain why some infected patients
also develop liver injury, fulminant myocarditis with subse-
quent heart failure, and diarrhea in addition to severe pneumo-
nia (35–38). In contrast to SARS-CoV, MERS-CoV uses the
enzyme dipeptidyl peptidase (DPP) 4 as receptor for host cell
entry (39). The median incubation time for CoV infections is
5 days but up to 2 weeks incubation time is not uncommon.
TheextraordinarilyhighspreadandthenumberofSARS-CoV-2
infections indicate that its infectivity is higher compared to SARS-
CoV,withabasicreproductivenumber(Ro)atapproximately3(40,
41); a recent estimate by the CDC defines the SARS-CoV-2 Ro at
approximately 5.7 (42). This may be explained by an improved
virus entry due to a molecular change of the receptor-binding
domainandthe insertionofa furin-cleavagesite in thespikeprotein
ofSARS-CoV-2; thisenablesa10-foldincreasedbindingaffinity to
ACE2 and fusion with the host cell membrane (43). SARS-CoV-2
mayadditionallyinfectepithelialcells intheupperrespiratorytract,
thereby facilitating transmission of the shed virus via respiratory
droplets.Presently, itappearsthatSARS-CoV-2ismorepathogenic
thantheinfluenzaAvirusbutlesspathogenicthanSARS-CoV(44);
the reported overall case fatality ratio of SARS-CoV-2 ranges
between 1.38 and 3.8 (1, 25, 45). Notably, wide testing and
identification of asymptomatic carriers versus focal testing
restricted to the hospitalized (symptomatic) patients may either
underestimate or overestimate the CRF.
IMMUNOPATHOGENESIS OF SARS-CoV-2
Given the vague COVID-19 pathogenesis, references to the
earlier SARS/MERS-CoV pandemics are inevitable. While
useful given the similar CoV origin, this is not ideal as several
significant immunological differences among the three diseases
are apparent (Table 2).
Upon infection, virus internalization typically evokes intra-
cellular pattern-recognition receptors signaling likely via RIG-
I, OAS (46), and TLR-7 inducing interferons (IFN) I/III (and
IFN-stimulated genes; IFGs) subsequently triggering a local
immune response. In uncomplicated COVID-19, an increase in
circulating follicular helper T cells and antibody secreting B
cells was observed (47) concurrent with an upregulation of
activation markers on CD14þ and CD8þ-T cells. In contrast,
there was a reduction of circulating CD14þCD16þ monocytes.
Interestingly, the systemic cytokine response has been typically
negligible in mild COVID-19, while rarely soaring in severe
COVID-19 cases (48–50). Such a scenario reflects an optimal
orchestration of the immune system and a balance between the
inflammatory response and disease tolerance leading to
uneventful pathogen eradication. Unfortunately, in a subgroup
of patients developing life-threatening COVID-19 phenotype
this balance is deranged. In the following sections, Table 2 and
Figure 3 summarize the rudimentarily understood dynamics of
the immuno-inflammatory processes in patients with varying
COVID-19 severity and phenotype.
Viral load
In adults, viral load was found to correlate with COVID-19
severity and has been suggested as a potential mechanism
responsible for the disease progression (51). However, the role
of the viral load is unclear since it may reflect failure of the
immune response and a high viral load can also be the result of
immuno-evasion (SARS-CoV-2 poorly upregulates IFN I and
III) (46). Endocytosis of the virions bounded to ACE2
decreases activity of this enzyme which can skew the angio-
tensin II/angiotensin (1–3, 5–8) balance by increasing ACE1
activity (52). It remains to be verified whether the increase in
angiotensin II indeed contributes to propagation of the inflam-
mation and impaired hypoxic vasoconstriction in COVID-19
patients. In human alveolar epithelial cells, SARS-CoV-2
induces cytopathic effects (53). SARS-CoV-2 appears to be
very cytotoxic; infection of epithelial Vero-E6 cells with a
patient-isolated SARS-CoV-2 strain was highly cytopathic after
48 h (M. Ranawak, personal communication). It can only be
TABLE 1. Main differences between COVID-19 and previous viral pandemics
COVID-19
2019–present*
MERS
2012–2019
Flu (H1N1)
2009
SARS
2002/03
Confirmed cases/
deaths worldwide
>4.7 Mill./ >315,000
in 213 countries
2,494/858
in 28 countries
3–5 Mill./200,000
(estimated values)
8,098/774
in 29 countries
Origin bat !? bat ! camel pig bat ! civet
median incubation time 5 days 5 days 2 days 5 days
Human-to-human transmission þþ /þ þþ þ
Receptor used for host cell entry ACE2 DPP4 Sialic acid residues ACE2
estimated case fatality ratio (CFR) 1.38%–3.8%† 34.4% <0.3% 9.6%
R0 1.4–5.7 0.3–0.8 1.4–1.6 2–5
Vaccination No No Yes No
Availability of therapeutic drugs No No Yes No
*As of May 18, 2020.
†Remains to be determined; CFR currently low in Germany, Taiwan, Singapore; high in Brazil, Italy, France, Spain, USA.
ACE indicates angiotensin-converting enzyme; DPP4, dipeptidyl peptidase 4; R0, basic reproduction rate; COVID-19, coronavirus disease 2019.
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TABLE 2. Comparison of selected aspects of immune response to SARS-CoV, MERS, and SARS-CoV-2*
Item SARS-CoV MERS SARS-CoV-2
Receptor abundance ACE2:
Lung and intestine epithelium
Endothelium
Cardiomyocytes
Central nervous system
Dipeptidyl peptidase 4 - DPP4
(CD26):
T-helper cells
Two receptor types
High expression in the placenta,
kidney; moderate expression in
the kidney, lung, liver
Low expression of 4.2 kb mRNA
only in the skeletal muscle,
heart, brain, pancreas
ACE2:
Lung and intestine epithelium
Endothelium
Cardiomyocytes
Central nervous system
Macrophages
Presumably CD147
Antibody: protection
and dynamics
Protection conferred
- 304 B cell epitopes
Seroconversion as early as (d4)
found in most patients by day 14
Long-lasting IgG and neutralizing
antibody up to 2 years
postinfection
Protection conferred MERS-CoV
reinfection can occur in
seropositive camels,
Transitory antibody response in mild
disease
Protection likely conferred
Common cross-reactivity in
antibody binding to the spike
protein
Rare cross-neutralization of the
live viruses
Highly variable neutralization
capacity across patients
Presence of non-neutralizing
antibody response to
conserved spike epitopes
Lymphocytes Prominent lymphopenia
(68%–85% cases)
Lymphopenia (35% cases) Lymphopenia (75% cases)
T-cell mediated immunity:
role and dynamics
Plays an important role in recovery
959 T cell epitopes
T cell responses correlate with
neutralizing ab
Human memory T-cell responses
specific for SARS-CoV
N protein persist for 2 years in the
absence of antigen
Airway memory CD4þ T cells
mediate protective immunity
Plays an important role in recovery
Robust virus-specific CD8 T-cell
responses
Late CD4 T-cell responses
Long-lasting T-cell immunity
(2 years)
T cell apoptosis present
Airway memory CD4þ T cells
mediate protective immunity
Unclear; under investigation
Activation of follicular T cells in
resolving infection
Signs of activation of memory
CD8þ T cells in resolution
phase
Macrophages and dendritic
cells: innate immunity
Low/no viral replication in
macrophages, DCs
Innate immunity able to control
SARS-CoV in the absence of
CD4/8 T cells and antibodies
Increased neutrophil and monocyte-
macrophages influx in severe/
lethal disease
Unclear; under investigation
Increase in CD14þCD16þ
monocytes in severe cases
Cytokine production
and dynamics
PBMCs expressing high level of
inflammatory cytokines
Large production in the lungs
Systemic elevation of IL-17 and
IFN I
No direct evidence for the
involvement of pro-inflammatory
cytokines and chemokines in
lung pathology during SARS and
MERS, correlative evidence from
patients with severe disease
suggests a role for hyper-
inflammatory responses in hCoV
pathogenesis
Mild/medium cytokine response
IL-6 and monocyte-related
chemokines are elevated in
the peripheral blood
Interferon production No type I IFN responses in cell
culture
No IFNa/ß induction in patients
Therapeutic IFN-I administration
protective in mice
Therapeutic IFN-b treatment
ineffective in inhibiting viral
replication in mice
Sensitive to in vitro type I IFN
pretreatment
Weak induction of IFN I and III
in vitro
Immune evasion Anti-type I IFN strategies preventing
its production and its effects
Anti-type I IFN strategies preventing
its production and its effects
Unclear; under investigation
*Due to the similar origin and genome, the immune response to human coronaviruses shares several confirmed and assumed aspects but numerous
differences have already been reported. The characterized immune responses are of relevance to their pathophysiology and treatment (36–38).
ACE indicates angiotensin-converting enzyme; CoV, coronavirus; DC, dendritic cell; IFN, interferon; IL, interleukin; MERS, Middle East Respiratory
Syndrome; PBMC, peripheral blood mononuclear cell; SARS, Severe Acute Respiratory Syndrome.
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hypothesized that, similarly to SARS-CoV, SARS-CoV-2 acti-
vates the NLPR3 inflammasome leading to pyroptotic cell
death (54); an abundant serum lactate dehydrogenase release
in severe COVID-19 supports this notion (55). Interestingly, in
bats, MERS-CoV poorly activates the inflammasome which
contributes to their disease tolerance (56).
Innate immunity
Even in severe COVID-19, a mild neutrophilia is typically
observed (48, 49), while circulating monocyte counts typically
remain unaltered (49). An increased fraction of CD14þCD16þ
cells was reported in severe cases (57) and several groups found
blood monocytes IL-1bþ, IL-6þ with IFGs expression (57, 58).
Monocytes in COVID-19 were found to reduce their Human
Leukocyte Antigen – DR isotype expression but the magnitude
and time course of that reduction remains to be determined (59,
60). This suggests a pathological role of inflammatory mono-
cytes in the immune response to SARS-CoV-2. Moreover,
transcriptomic analysis of peripheral blood mononuclear cells
(PBMCs) revealed upregulation of complement-related genes
and increase in C-C motif ligand (CCL)2, C-X-C motif
ligand10, CCL3, and CCL4 chemokines expression (61).
Importantly, the CD169þ macrophages can be stimulated
and infected by the virus up-regulating IL-6 (62). In some
severe COVID-19 patients, high circulating ferritin was
reported suggestive of hemophagocytosis by activated macro-
phages (48, 60).
Adaptive immunity
Severe cases of COVID-19 are characterized by peripheral
lymphopenia attributable to the loss of T-cells, while B and NK
cells remain only marginally affected (48, 49). Mechanisms of
the T-cell lymphopenia remain mostly hypothetical but upre-
gulation of pro-apoptotic genes expression has been suggested
(61). Hallmarks of apoptosis and necrosis were present in
lymph nodes and spleens in three autopsied COVID-19 patients
(62). Alternatively, lymphopenia may be due to a robust lung
infiltration and tissue homing (of circulating lymphocytes)
which needs to be verified in further autopsy studies. Differen-
tiating between these two mechanisms is key for understanding
the pathophysiology and potential treatments. The circulating
CD4þ and CD8þ T-cells are activated, but there is discrepancy
in the available reports regarding their ability to produce IFN-g
(49, 63). Notably, in aged mice, CD4þ but not CD8þ T-cells
were crucial in controlling interstitial inflammation and clear-
ing SARS-CoV-infection (64). One group reported an increased
frequency of central memory with a decrease in naive T-cells
subpopulations and clonal expansion of cytotoxic CD8þ T cells
(58), while another group showed a rise in the frequency of
naive CD4þ T-cells (49). It can be hypothesized that an
uncontrolled ‘‘bystander activation’’ (in a cytokine-dependent
manner) of the cytotoxic T-cells and their tissue sequestration
are among the major pathogenic events which is supported by
activation markers in severe cases (63). Interestingly, only in
the ICU-admitted patients the pathogenic GM-CSFþIFN-gþ
CD4þ-T cells were found (57). Simultaneously, the regulatory
T cells decrease (49) suggesting an impairment of the immune
regulation. A single-cell analysis revealed an increase in mem-
ory B and plasma cells, which maintained activation and
antibody production (with IgA overrepresentation) (58). Most
antibody-related findings indicate that specific anti-SARS-
CoV-2 immunoglobulins possess a neutralizing potential in
vitro (65). However, the role of antispike protein antibodies
should be further evaluated as these molecules may aggravate
COVID-19 by promoting proinflammatory monocyte activa-
tion (66) and enable infection of immune cells (67). Those
cellular changes were accompanied by seroconversion and
appearance of Immunoglobulin G (IgG) and Immunoglobulin
M (IgM) immunoglobulins. However, seroconversion takes
from 5 to 9 days (68–70). Whether this humoral immunity
is fully protective or could also contribute to antibody-depen-
dent immunopathology (71, 72) remains to be established.
Nevertheless, when studied in vitro, a correlation was reported
between antibody titers and neutralization properties. At pres-
ent, several studies investigate convalescent plasma-containing
antibodies for treatment (73, 74).
Cytokines
Despite evidence of the so-called ‘‘cytokine storm’’ in SARS
and MERS (75, 76), recent data suggest that this is not
necessarily the case in SARS-CoV-2 infection (48, 51). Con-
flicting viewpoints backed by yet insufficient data have
emerged fueling controversy about this concept (77, 78).
Circulating cytokines (both pro- and anti-inflammatory)
FIG. 3. Summary of potentially protective and harmful host responses during the SARS-CoV2 infection based on the currently available data. ASC
indicates antibody secreting cells; BM, bone marrow; CTL, cytotoxic T-cells; IFN, interferon; Tfh, follicular helper T-cells; SARS-CoV-2, severe acute respiratory
syndrome coronavirus 2.
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increase in COVID-19 patients; however, only some of them
(e.g., IL-2, IL-7, IL-10, G-CSF, MCP1, TNFa) are relatively
robustly increased in severely (ICU-admitted) ill patients when
compared with moderate/mild cases (48, 51). Compared with
hyperreactive responses recorded in bacterial septic patients
(79) and after noninfectious triggers (80), the cytokine upre-
gulation in COVID-19 appears to be at least one log of
magnitude lower. Many controversies arise regarding IL-6 as
this cytokine was shown to be slightly increased in some
severely ill (51), while it was also markedly up-regulated in
non-survivors (81) and critically ill COVID-19 patients (82).
Others found IL-6 predictive of mechanical ventilation require-
ment at a cutoff of 80 pg/mL (83). Of note, the expression of IL-
6R in bronchoalveolar lavage fluid cells was downregulated
and unchanged in PBMCs, suggesting that this pathway may
not be crucial for COVID-19 pathophysiology (61). The current
rationale to inhibit IL-6 is also controversial as IL-6 promotes
antibodies formation (84), regeneration of airway ciliated cells
from basal stem cells (85) and protects against H1N1 influenza
(86). An indiscriminate application of IL-6 (and other) blockers
has potential for harm, especially when done in a ‘‘blind’’
fashion in a heterogenous population of COVID-19 patients.
The interferons
The precise role of IFNs in SARS-CoV-2 infection is yet
unclear and requires further investigation. It is unclear whether
patients by default produce amounts of interferon like certain
mammals (87) or low IFN concentrations may reflect the
coronaviruses’ capacity to prevent/reduce its production and
action (88–95). The latter may be plausible given that CoV are
well capable of preventing NF-kB activation (96) and protein
translation (97). It is also important to define the specific role
played by IFN-e in the mucosa; this may explain differences
between humans versus bats/pangolins regarding their response
to a CoV infection (98–100). Better understanding of the
crosstalk between SARS-CoV-2 and IFNs will offer insights
into the COVID-19 immunopathogenesis. Some data suggest
that the strategy of a very early administration of type I IFN
could be considered (101–103). However, the negative effect of
a late exposure to IFNs must also be considered; a study
combining single-cell RNA-sequencing data and in vitro anal-
ysis showed that ACE2 is upregulated by type I and II IFNs in
human and primate airway epithelial cells (104). Furthermore,
IFN-inducible genes are highly expressed in cells from bron-
cho-alveolar lavage fluid of COVID-19 patients and exhibited
pathogenic potential with overrepresentation of genes involved
in inflammation (105). Of note, the National Institute of Health
(NIH) recommends against the use of IFNs for the treatment of
COVID-19 outside of clinical trials (https://www.covid19treat-
mentguidelines.nih.gov/therapeutic-options-under-investiga-
tion/host-modifiers-immunotherapy/). Carefully designed
trials will hopefully inform on the potential of the type I
interferon application (106).
Coagulopathy and endotheliopathy
Coagulopathy appears to be a critical element in the context of
severe COVID-19 courses. Elevation of D-dimers (fibrin degra-
dation products) has been frequently observed in severe cases
and identified as a significant risk factor (107). One study
revealed presence of a procoagulant state even during the early
COVID-19 stage (21) and disseminated intravascular coagula-
tion has been diagnosed in most critically ill patients (108).
Moreover, the incidence of thromboembolic events is high
(comparable to sepsis) and most likely underdiagnosed (109).
It can be hypothesized that there is dominant local pulmonary
vessel microthrombosis which correlates with the severity of
hypoxemia and high compliance (110) and stays in accordance
with fibrin accumulation found in the lungs (110, 111). Presum-
ably, there are several pathways which may contribute to the
clinical coagulopathy observed. Direct infection of the endothe-
lium, thereby triggering endothelial injury, inflammation, and
cell death (22), can directly activate the coagulation cascade.
Pyroptosis and inflammasome-released mediators are other
potent coagulation cascade activators (112, 113). Histopatholog-
ical examination revealed deposition of activated complement
complexes that may propel microvascular injury and subsequent
activation of the clotting pathway (114). Neutrophilic infiltrates
can also activate coagulation through the generation of neutro-
phil extracellular traps (115) and a recent anecdotal study
confirmed the presence of antiphospholipid antibodies in three
COVID-19 patients with severe coagulopathy (116). An analysis
of over 3,500 genes (differentially expressed in the lungs)
following murine SARS-CoV infection identified various pro-
coagulatory factors (especially urokinase) to be strongly associ-
ated with mortality (116). Urokinase activity results in the
generation of plasmin and in turn in fibrinolysis with elevated
D-dimers manifested by alveolar coagulopathy and pulmonary
hemorrhage. Furthermore, serpin1 knockout mice confirmed an
enhanced pulmonary expression of procoagulatory and profi-
brinolytic proteins and clinical susceptibility to SARS-CoV
(117). Apart from cytokine effects on the pulmonary endothe-
lium, it has also been proposed that disruptions of the kallikrein-
bradykine axis can increase microvascular permeability and
cause angioedema (118).
EXPERIMENTAL THERAPIES AND PRECLINICAL
EVIDENCE
The number of proposed therapeutic strategies against
COVID-19 grows weekly; presently, there are over 50 sub-
stances considered as potential remedies including brand new
(Small interfering RNA) (119)) as well as well-known/repur-
posed chemicals (chloroquin, interferons, remdesivir). Yet, the
currently available pre- and clinical evidence supportive of the
experimental therapies is suggestive at best. Several substances
with different targets have been proposed based on sparse peer-
reviewed publications (Table 3) (120–143); some based on
non-peer-reviewed (medRxiv and bioRxiv) preprints and/or
anecdotal evidence only. As of May 19, 2020, there is only
one peer-reviewed study (140) that tested an anti-COVID-19
candidate drug in a relevant SARS-CoV-2 animal model
(Table 3); many drugs have not yet been directly tested against
SARS-CoV-2 in vitro. Except a single case (140), the only
available animal model-based evidence stems from MERS/
SARS-CoV studies (Table 3), but these diseases are not identi-
cal to COVID-19 (Table 2).
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TABLE 3. Preclinically tested therapeutics against SARS-CoV, MERS-CoV, and SARS-CoV-2 and related illness*
Area of activity Substance administered Corona virus type Findings Animal/cell model(s)
Viral replication Remdesivir 1. MERS-CoV
2. MERS/SARS-CoV,
human CoV, batCoV
3. MERS-CoV
4. SARS-CoV-2
1. Prophylactic/therapeutic; viral replication
inhibition, reduced lung lesions
2. Prophylactic/therapeutic; viral replication
inhibition, improved respiratory function
3. Prophylactic/therapeutic; reduced viral
replication and ALI, prevented mortality
4. Pre-/co-/post-treatment; blocked cell entry,
reduced viral replication
1. NHP (120)
2. pHAEC, pHLC, mouse
(121)
3. Mouse, Calu-3 cells (122)
4. Vero E6 (123, 124)
siRNA SARS-CoV Prophylactic/therapeutic; viral replication
inhibition, reduced lung lesions
NHP (125, 126)
NHC (cells)
NHC prodrug
(mouse)
1. MERS-CoV
2. SARS-CoV
3. SARS-CoV-2
1. Prophylactic/therapeutic; reduced viral
replication, increased viral mutation rates
(cells), reduced lung lesions and improved
respiratory function (mouse)
2. Prophylactic/therapeutic; viral replication
inhibition (cells and mouse), improved
respiratory function and reduced lung lesions
(mouse)
3. Reduced viral replication
1. Calu-3, pHAEC cells,
mouse (127)
2. Calu-3, pHAEC cells,
mouse (127)
3. Calu-3, Vero, pHAEC cells
(127)
Cell/nuclear entry Chloroquine (CQ) and
hydroxychloroquine
(HCQ)
1. SARS-CoV-2
2. SARS-CoV
1. Pre-/post-treatment; blocked/reduced cell entry,
reduced viral replication, inhibitory efficiency
HCQ>CQ
2. Therapeutic; no effect on viral replication
1. Vero E6 (123, 128, 129)
2. mouse (130)
camostat mesylate SARS-CoV-2 Pre-treatment; reduced cell entry Calu-3 cells (131)
Ivermectin SARS-CoV-2 Post-treatment; reduced viral replication Vero/hSLAM (in press)
Immuno-
inflammatory-
modulation
Mycophenolic acid MERS-CoV 1. Therapeutic; viral replication and mortality
exacerbation
1. NHP (132)
theta-defensin 1 SARS-CoV Prophylactic/therapeutic; prevented mortality,
reduced lung lesions and
pro-inflammatory markers
Mouse (133)
Pentoxifylline SARS-CoV Therapeutic; no effect on viral replication Mouse (130)
antibody:
1–3. anti-SARS-CoV
4. anti-C5a
1–3. SARS-CoV
4. MERS-CoV
1. Prophylactic/therapeutic; viral infection inhibition,
reduced lung lesions
2. Prophylactic; viral infection inhibition
3. Prophylactic/therapeutic; reduced viral load and
lung lesions
4. Prophylactic/co-application; reduced viral
replication, lung/spleen lesions and pro-
inflammatory markers
1. Mouse (134)
2. Hamster (135)
3. NHP (136)
4. Mouse (137, 138)
Interferon (a/ ß1b) 1. SARS-CoV
2. MERS-CoV
3. SARS-CoV
1. Prophylactic/therapeutic; viral replication
inhibition, reduced lung lesions
2. Therapeutic; viral replication inhibition, improved
survival
3. Therapeutic; viral replication inhibition
1. NHP (139)
2. NHP (132)
3. Mouse (130)
Other compounds 1. Lianhuaqingwen
2. Pudilan xiaoyan
SARS-CoV-2 1. co-/post-treatment; reduced viral replication
(Vero E6), reduced pro-inflammatory markers
(Huh-7)
2. therapeutic; reduced viral load & lung lesions
1. Vero E6 and Huh-7 (124)
2. Mouse (140)
Combinations 1. Lopinavir/ritonavir
2. Lopinavir/
ritonavir/IFNb
3. IFN-a2b and
ribavirin
MERS-CoV (1–3),
SARS-CoV (1&3)
1. Therapeutic (NHP); viral replication inhibition,
improved survival. Cotreatment (FRhK-4);
reduced cytotoxicity
2. Prophylactic/therapeutic; minimal effects
3. Therapeutic; reduced lung lesions, improved
respiratory function, reduced pro-inflammatory
markers
1. NHP (132), FRhK-4 (141)
2. Mouse, Calu-3 cells (122)
3. NHP, Vero and LLC-MK2
cells (142, 143)
*Data on the following coronaviruses are included: MERS-CoV, SARS-CoV, SARS-CoV-2, human CoV, bat CoV. Complete in vitro record is provided for
SARS-CoV-2 only. Only peer-reviewed publications are included (May 19, 2020).
FKrH-4 indicates fetal rhesus kidney cells; Huh-7, hepatocyte derived cellular carcinoma cell; LLC-MK2, rhesus monkey kidney epithelial cells; MERS,
Middle East Respiratory Syndrome; NHC, N4-hydroxycytidine; NHP, non-human primate; pHAEC, primary human airway epithelial cell; pHLC, primary
human lung cells; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; siRNA, Small interfering RNA. Prophylactic administration: before
virus inoculum, therapeutic administration: after virus inoculum.
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Mechanistically, we are only at the very beginning to under-
stand how SARS-CoV-2 infects, targets the lungs (and other
organs), and causes severe vascular and tissue damage. Despite
the aforementioned limitations, the existing experimental find-
ings warrant a well-organized, collaborative verification of
therapeutics aiming at clearing the virus load, modulating
the inflammatory response, protecting/repairing damaged tis-
sues (e.g., endothelium), and ameliorating vascular coagulop-
athy. The mechanisms of pulmonary and remote organ response
to SARS-CoV-2 present an additional level of complexity; any
pathophysiological (and subsequently therapeutic) leads
remain mostly speculative and require adequate modeling
and experimental verification. This is currently difficult to
achieve given that (mostly non-peer-reviewed) evidence sug-
gests the only animal models suitable for studying SARS-CoV-
2/COVID-19 include non-human primates, ferrets, and trans-
genic mice. The WHO asserts high reproducibility of SARS-
CoV-2 infection in Rhesus macaques and ferrets (144). Macaca
mulatta was the most susceptible to SARS-CoV-2 (compared
with M fascicularis and C jacchus) displaying a wide array of
clinical-like COVID-19 symptoms (145). In another study, six
macaques developed infection and pneumonia but remained
asymptomatic (120). Kim et al. (146) demonstrated ferrets as an
apt model both for SARS-CoV-2 infection and transmission;
animals were symptomatic (e.g., fever, cough), displayed high
viral RNA in the lungs and upper respiratory tract and shedded
virus via multiple routes. The disease phenotype in ferrets was
reproduced by another study (147) and there is unpublished
evidence from the Australian Centre for Disease Preparedness,
Geelong, Victoria.
However, small laboratory animals remain the most accessible
and cost-effective model to study. Transgenic human ACE2 mice
(both sexes) infected with the HB-01 strain developed COVID-
19-like interstitial pneumonia, high viral load, and produced high
specific IgG titer but the disease was generally mild (148). The
most recent study largely reproduced this phenotype in hACE
mice (149). Syrian hamsters constitute another potential option;
two groups recently recapitulated a mild but widely symptomatic
COVID-19 phenotype (150, 151). In contrast, species such as
pigs, chickens, and ducks were virus-free when either inoculated
or exposed to the virus, cats were asymptomatic despite postex-
posure infection whereas dogs were minimally susceptible to
SARS-CoV-2 exposure (152). Experimental drugs will soon be
tested in the newly emerging COVID-19 models. While model-
ing of SARS-CoV-2 infection in healthy and young animals will
be informative, it is important to consider that the most severe
COVID-19 phenotypes appear in aged patients with comorbid-
ities—the animal models should reflect this to maximize their
translational capability for pathophysiology studies and drug
testing. The most recent macaque experiment attests to that; 15-
year-old animals developed an exacerbated COVID-19 pheno-
type while the young ones did not (153). Another important
element in preclinical modeling is to promote study designs that
allow drug testing in divergent, precisely defined and relatively
homogeneous COVID-19 phenotypes (provided they can be
recapitulated in animals). It is likely that a given therapeutic
may be either beneficial or detrimental contingent upon the
timing of its administration and/or specific COVID-19
pathophysiological characteristic. Compared with patients, ani-
mal studies present a relatively cheap and safe platform to
establish such relationships.
The yet limited evidence derived from preclinical studies
coupled with the emerging clinical data as discussed previously
indicates that SARS-CoV-2-induced coagulopathy may be one
of the key interests for experimental studies (116). In this context,
another less apparent but interesting target for potential COVID-
19 therapy is the complement activation pathway. Genetic
absence of the complement C3 component was associated with
reduced pulmonary/systemic inflammation and improved lung
function (154). MERS-CoV-infected mice displayed elevated
complement component C5a in the lungs and blood and blockade
of the C5aR receptor attenuated inflammation in the lungs and
spleen and reduced pulmonary viral replication (137). As afore-
mentioned, adaptive immunity cells activation is prerequisite for
eradication of the virus. Whether specific cell types of adaptive
immune cells may help to induce pulmonary healing processes in
SARS-CoV is currently unclear. Mechanistically, the large sur-
face area of the alveolar capillary endothelium appears as a key
target organ; protection and repair of the dysfunctional air–blood
barriers (through reduction of endothelial swelling, damage,
boosting epithelial regeneration) and endothelium-derived coa-
gulopathy (e.g., formation of microthrombi) could be life-saving
in COVID-19 patients, especially in those with advanced pul-
monary damage and severe respiratory failure. Unfortunately,
these postulates remain largely speculative and valid SARS-
CoV-2/COVID-19 models are needed for verification.
An application of experimental (unlicensed) therapeutics via
the compassionate use protocol (CUP) while justified as last
resort (155) should not be reflexively overexpanded in the
context of SARS-CoV-2/COVID-19 infection; CUP rarely
provides reliable efficacy data given multiple confounding
factors and inobjectivity. Whereas the magnitude of pandemia
may justify extraordinary measures to save patients’ lives, these
measures must be counterbalanced by an extraordinary analyt-
ical rigor and resistance to overoptimistic interpretation of the
daily-emerging in vitro/silico, animal and clinical data. In a
disease with a relatively low mortality and rudimentary under-
standing of its pathophysiology, potential risks for life-threat-
ening side effects by unproven therapeutics must not be ignored
in a pursuit of the desired benefits. The hazards of adverse
effects are additionally aggravated by the typically advanced
age of COVID-19 patients, who frequently present with various
comorbidities and comedications (156). Properly designed
animal experiments and clinical studies will gradually reveal
the cons and pros of the experimental therapeutics.
CLINICAL MANAGEMENT AND TRIALS
With the exception of remdesivir, which has received an
emergency use authorization by the US Food and Drug Admin-
istration (FDA) for the treatment of hospitalized COVID-19
patients on May 1, 2020, (European Medical Agency (EMA)
announced on May 18, an upcoming conditional marketing
authorization), there are no drugs yet approved by any profes-
sional authority to prevent and treat COVID-19; results from
any large-scale clinical trials are not yet available. The WHO,
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EMA, and CDC strongly discourage the application of any
unlicensed therapeutics outside of adequately designed clinical
trials (https://www.cdc.gov/coronavirus/2019-ncov/hcp/thera-
peutic-options.html#r8; https://apps.who.int/iris/bitstream/
handle/10665/331446/WHO-2019-nCoV-clinical-2020.4-eng.
pdf?sequence=1&isAllowed=y; https://apps.who.int/iris/han-
dle/10665/330680). The most reliable strategies continue to
rest on supportive ICU care practices including supplemental
oxygen, mechanical ventilation, and, in extremis, extracorpo-
real membrane oxygenation. However, traditional ventilation
protocols used in acute respiratory distress syndrome (ARDS)
may not be adequate for all COVID-19 patients. Interim guide-
lines to inform clinicians how to care for patients with COVID-
19 have been released by the NIH (https://covid19treatment-
guidelines.nih.gov/introduction/) and by the Surviving Sepsis
Campaign as an initiative supported by the Society of Critical
Care Medicine and the European Society of Intensive Medicine
(SCCM/ESICM, (157)). Health professionals from the Euro-
pean Respiratory Society partner societies have compiled an
international directory of guidelines and best practice recom-
mendations documents intended to help share COVID-19
expertise around the world (https://www.ersnet.org/covid-19-
guidelines-and-recommendations-directory). However, the
guidelines are based upon current limited evidence and will
require rapid updates to account for any new and compelling
evidence; the NIH guidelines are conceptualized as living
guidelines (158). Some of the more prominent, currently
investigated therapies include antimalarials, antivirals, immu-
notherapeutics, and corticosteroids (158).
Antimalarials
The trial-based evidence has been fluctuating very dynami-
cally since the dawn of the SARS-CoV-2 pandemic. Initially, it
was proposed to treat severely ill Chinese COVID-19 patients
with chloroquine phosphate (159). Following these observa-
tions, a combination of oral hydroxychloroquine and azithro-
mycin was proposed in patients with signs of lower respiratory
tract involvement. This was based on a small-scale open-label
clinical trial, in which 36 patients were allocated to treatment
with hydroxychloroquine (n¼ 20) or left untreated (n¼ 16).
Hydroxychloroquine was associated with virological cure on
days 3, 4, and 5 in 50%, 60%, and 70%, respectively, compared
with 6.3%, 25%, and 12.5% of untreated controls (azithromycin
co-administration in six patients further improved it to 83%)
(160). This French study was further confirmed by the same
team on 80 patients (161). These studies were heavily criticized
by the MRC-NIHR Trials Methodology Research Partnership
for numerous shortcomings (160). The two subsequent studies
with hydroxychloroquine indicated no improvement (162,
163). The most recent reports emphasize risks associated with
chloroquine-based trials; due to adverse cardiac reactions,
chloroquine treatment (with and without azithromycin) was
stopped in Brazilian (164) and French (165) trials; and several
hospitals in Sweden stopped administering hydroxychloro-
quine to COVID-19 patients based on similar findings (166).
A recent preprint article that retrospectively analyzed hydroxy-
chloroquine use in hospitalized US veterans found an associa-
tion of increased overall mortality with its use (167).
Antivirals
Other suggested alternatives have been antiviral treatments with
remdesivir and lopinavir-ritonavir. The most recent remdesivir
CUP study was performed in 53 patients with severe COVID-19
and the median follow-up showed an improvement in oxygen
support in 36 patients (68%) including 17 of 30 patients (57%)
with mechanical ventilation that were successfully extubated
(168). However, the study has been widely questioned as no
comparator group was involved (https://www.sciencemediacen-
tre.org/expert-reaction-to-a-study-about-compassionate-use-of-
remdesivir-for-patients-with-severe-covid-19/). Another open-
label randomized trial in 199 COVID-19 patients showed that
lopinavir-ritonavir failed to accelerate clinical improvement,
reduce mortality, and diminish viral RNA detectability (169).
Nearly 14% of patients in the lopinavir-ritonavir arm could not
complete the full 14-day treatment course due to gastrointestinal
adverse events. Remdesivir and (hydroxy) chloroquine are both
under evaluation in the largest international trial in severe COVID-
19 patients launched by the WHO and partners. The ‘‘SOLIDAR-
ITY’’ trial compares four options: local standard of care (LSC), or
LSC plus either remdesivir, chloroquine/hydroxychloroquine,
lopinavir with ritonavir, or lopinavir with ritonavir plus IFNß-
1a. As of May 18, 2020, over 90 countries are active participants to
this trial (https://www.who.int/emergencies/diseases/novel-coro-
navirus-2019/global-research-on-novel-coronavirus-2019-ncov/
solidarity-clinical-trial-for-covid-19-treatments). As the most
recent development, results of two different randomized, pla-
cebo-controlled, multicenter studies testing remdesivir were
released on April 29, 2020: the Chinese trial (NCT04257656;
237 patients; (170)) demonstratedno statistical benefit, whereas an
official announcement (apnews.com) stated that an NIH-led trial
(NCT04280705; 460 patients at interim analysis) shortened the
time to recovery to 31%. Two days later, on May 1, 2020, the FDA
approved remdesivir for emergency use to treat COVID-19
patients based upon the belief that ‘‘the known and potential
benefits of [remdesivir] outweigh the known and potential risks of
the drug for the treatment of patients hospitalized with severe
COVID-19’’ (https://www.fda.gov/media/137564/download).
Immuno-inflammatory modulation
Various strategies aiming to modulate the immune response
in critically ill COVID-19 patients have been proposed. Spe-
cific examples include the transfusion of convalescent plasma
and targeted anti-inflammatory treatments. In two case-series
critically ill COVID-19 patients (171, 172) received compati-
ble transfusions of 250 mL to 400 mL of convalescent plasma.
In the first case-series (171), all five patients were under co-
administration of methylprednisolone and antivirals (mainly
lopinavir/ritonavir). After 12 days from transfusion, an
improvement was noted in the Sequential Organ Failure
Assessment score, an increase of the partial oxygen to fraction
of inspired oxygen (pO2/FiO2) ratio along with virological
cure was observed (172). In the second case-series, clinical
improvement was not observed in the 10 enrolled patients but
all patients experienced virological cure (172). Three trials
testing convalescent plasma in COVID-19 patients are cur-
rently recruiting patients (NCT04321421; NCT04343755;
NCT04355897).
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The idea of modulating the immune response of the host
originates from the observed alterations of various cytokines in
the blood of COVID-19 patients (49, 60, 172). For example,
circulating cytokines were compared between 286 severe and
166 non-severe COVID-19 patients; TNFa, IL-2 receptor, IL-6,
IL-8, and IL-10 were significantly higher in the severe versus
non-severe patients. Another recent study analyzed immune
characteristics of 54 COVID-19 patients with (n¼ 28) or
without (n¼ 26) mechanical ventilation requirement suggest-
ing two divergent dysregulation patterns: a generalized immune
hyperactivation and dysregulation associated with a decreased
Human Leukocyte Antigen – DR isotype expression (60).
Several clinical trials are currently testing a range of inflam-
matory modulators; four medium-size trials investigate the
efficacy of biologically targeting the IL-1 and the IL-6 path-
way: recombinant IL-1 receptor antagonist anakinra
(NCT04330638/COV-AID, 342 patients), IL-6 receptor antag-
onists tocilizumab (NCT04330638/COV-AID, 342 patients;
NCT04320615/COVACTA, 330 patients), and sarilumab
(NCT04320615/CORIMUNO-SARI, 240 patients). Mortality,
ventilator-free days, and the change of the respiratory ratio are
the most common endpoints. Smaller-scale trials also aim (not
yet recruiting) to investigate the impact of immunostimulants
like PD-1 blockers thymosine (NCT04268537; 120 patients)
and novilumab (NCT04343144/CORIMUNO-NIVO, 92
patients), and Treg stimulant human recombinant IL-
2 (NCT04357444/LILIADE-COVID, 30 patients). However,
these strategies are not controversy-free given that there is
no clear consensus as to what extent the magnitude of the
inflammatory response generated by SARS-CoV-2 is detrimen-
tal to COVID-19 patients (hence favoring cytokine inhibition)
or necessary for eradication of the virus and host defense (hence
discouraging their blockage and/or favoring immuno-support-
ive interventions).
Corticosteroids
The use of corticosteroids in the acute respiratory distress
syndrome (ARDS) of COVID-19 remains also a matter of debate
as no evidence of their efficacy currently exists. In a recent report in
84 COVID-19 patients with ARDS, the administration of methyl-
prednisolone (dosage similar to the SCCM/ESICM recommenda-
tions (173)) was associated with a reduced risk of death (0.38; 95%
CI, 0.20–0.72) (107). Although opinions vary on the administra-
tionofcorticosteroidsinCOVID-19patients, thetwolargeststudies
on H1N1 and SARS (n¼ 7568) were supportive to their use (174,
175). However, the WHO interim (https://www.who.int/publica-
tions-detail/clinical-management-of-severe-acute-respi-
ratory-infection-when-novel-coronavirus-(ncov)-infection-is-
suspected) and NIH (https://covid19treatmentguidelines.nih.-
gov/introduction/) guidelines do not recommend corticosteroids
in viral pneumonia outside of clinical trials. There is preliminary
information from China and Italy, suggesting that the use of
corticosteroids in COVID-19-associated ARDS could be con-
sidered(176)butsuchanecdotalevidence isburdenedbybiasand
should not be used as reference for altering treatment practices.
The WHO has prioritized the evaluation of corticosteroids in
COVID-19 with five running randomized controlled trials. At
present, no definite conclusion can be drawn from the available
experimental and clinical data to assess the acute and long-term
effects of corticosteroids for the resolution of the local and
systemic inflammatory response in COVID-19 and/or the devel-
opment of fibrotic complications.
Coordinating clinical trials
An overwhelming number of clinical trials has emerged
(Fig. 4) aiming to assess therapies ranging from antivirals,
immune-therapeutics, and host-directed therapies, vitamins,
gases, mesenchymal stem cells to Traditional Chinese Medicine
—all in the bid to save lives of COVID-19 patients. As of May 18,
FIG. 4. Global clinical research activities on SARS-CoV2/COVID-19 based upon trial registration data. A, Registration of COVID-19 clinical trials for
each day. B, The cumulative number of registered COVID-19 clinical trials exceeds 1,500. Information based on data from the WHO Clinical Trials Search Portal
(https://apps.who.int/trialsearch/) for COVID-19-related clinical trials as of May 18, 2020. This portal allows access to a central database containing the trial
registration data sets provided by international registries. The WHO portal is updated every Friday by six important registries and every 4 weeks by additional
registries (https://covid-19.heigit.org/clinical_trials.html; COVID-19-Karte der Hoffnung; Universität Heidelberg; May 18, 2020). COVID-19 indicates coronavirus
disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
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2020, the cumulative number of registered COVID-19 clinical
trials according to the WHO Clinical Trials Portal was 2356
(https://www.who.int/ictrp/en/). The trial count grows daily and
is frequently updated. The deluge of trials scheduled to recruit
simultaneously may create a realistic ‘‘traffic jam’’ risk for under-
enrolment and is perceived as chaotic (177). An additional major
concern of many ongoing COVID-19 trials is their relatively low
power to detect significant differences in meaningful outcomes.
Low-powered trials rarelyprovideunequivocal evidence justifying
the use of tested therapeutics. In this respect, pandemics provide a
unique window of opportunity for large-scale collaborative initia-
tives, thus, enabling networks to jointly generate and address
common goals as well as to standardize data collection in large
patient volumes. The WHO recommends the development of
‘‘Master Protocols’’ for high-powered, adequately-designed trials
asa tool for themost rapidand reliableevaluationofinvestigational
therapeuticsandvaccines(https://www.who.int/blueprint/priority-
diseases/key-action/novel-coronavirus/en/). The five ongoing
global clinical trials SOLIDARITY (https://www.who.int/emer-
gencies/diseases/novel-coronavirus-2019/global-research-
on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-
for-covid-19-treatments), REMAP-CAP (A Randomised,
Embedded, Multifactorial, Adaptive Platform Trial for Commu-
nity-Acquired Pneumonia; (NCT02735707; remapcap.org
(178), RECOVER (Randomized Evaluation of COVID-19 Ther-
apy; https://www.recoverytrial.net/; https://doi.org/10.1186/
ISRCTN50189673) and PRINCIPLE (Platform Randomized
trial of Interventions against COVID-19 in older people;
ISRCTN86534580 (179), and Trial of Treatments for COVID-
19 in Hospitalized Adults (DisCoVeRy) (https://clinicaltrials.-
gov/ct2/show/NCT04315948(180)exemplifysuchanapproach.
Vaccines
Finding a safe and effective vaccine to prevent infection with
SARS-CoV-2 has become an urgent public health priority and a
number of legacy drug-makers and startups have begun to
develop vaccines (and treatments) that target SARS-CoV-2.
At present, the global COVID-19 vaccine R&D landscape
includes 115 vaccine candidates, of which 78 are confirmed
as active and 37 are unconfirmed ((181), https://clinicaltrials.-
gov/). Of the 78 confirmed active projects, 73 are currently at
exploratory or preclinical stages. The most advanced candi-
dates have recently been moved into clinical development,
including mRNA-1273, Ad5-nCoV, INO-4800, LV-SMENP-
DC, and pathogen-specific aAPC (181). On March 16, 2020,
the first-ever injection of an investigational vaccine for SARS-
CoV-2 (mRNA-1273) was administered to four volunteers
participating in an open-label phase 1 clinical trial in the United
States. The study is expected to conclude June 1, 2021. Multiple
other vaccine developers have communicated plans to initiate
human testing within this year.
SARS-CoV-2 DIAGNOSIS AND OPTIMIZATION OF
TESTING
The differentiation of the SARS-CoV-2-positive cases from
the healthy is among the main clinical challenges. Many
asymptomatic persons are a source of infection despite being
considered healthy prior to a positive test result (182). The
prevalence of asymptomatic (SARS-CoV-2 positive) patients
ranges between 1.5% and 30% (182–184). Non-test-based
COVID-19 diagnosis is difficult given that the most common
clinical symptoms, e.g., fever, fatigue, dry cough, myalgia, and
dyspnea (51, 185) are unspecific and overlap with other viral
diseases (185). Several hematologic and immuno-inflamma-
tory abnormalities observed in SARS-CoV-2-positive patients
resemble MERS/SARS-CoV infection symptoms (185). To
reduce the transmission risk, aggressive containment, mitiga-
tion, and treatment strategies must be combined and rapid and
accurate testing is key. A few countries/territories such as
Taiwan, Hong Kong, Singapore, and South Korea have rapidly
implemented aggressive testing (186); South Korea has per-
formed >300,000 tests (5,829 tests/million population) within
the 9 weeks after the first SARS-CoV-2 case was identified,
effectively containing the SARS-CoV-2 spread (187, 188). The
majority of other countries have been struggling with tests
approval, availability, and/or operationalization of high-
throughput testing, which was accompanied by substantial
differences in reported numbers.
The current recommendation of many professional radiolog-
ical associations and societies is that imaging should not be
employed as a screening nor diagnostic tool for COVID-19 but
reserved for the evaluation of complications. Although used
frequently in early reports with some characteristic features
described ((4), Fig. 2), imaging has limited sensitivity for
COVID-19 and the definitive test for SARS-CoV-2 remains
laboratory-based. A wider evaluation of the CT value in
COVID-19 patients is further complicated by its different
use among different countries (e.g., frequent in China, infre-
quent in Europe, sporadic in the US).
As of March 9, 2020, the WHO recommends testing based on
clinical and epidemiological factors contingent on the likelihood
of SARS-CoV-2 infection and/or exposure (189). Similarly, the
CDC has established a priority system for diagnostic testing for
SARS-CoV-2 infection based on the availability of tests; the
CDC testing guidance is updated periodically (https://covid19-
treatmentguidelines.nih.gov/overview/). In asymptomatic or
mildly symptomatic subjects who were in contact with SARS-
CoV-2/COVID-19, virus nucleic acid amplification tests
(NAAT), such as RT-PCR, is typically recommended (189).
Given that NAAT recommendations are difficult to meet in many
countries due to limited testing resources and/or excessive
demand, the WHO suggests adopting screening protocols tai-
lored to the local situation and provides reference laboratories for
confirmatory testing (https://www.ecdc.europa.eu/en/novel-
coronavirus/laboratory-support) as well as shipment instructions
if local testing is unavailable (190). As co-infections and false-
negative diagnoses occur, testing for other respiratory pathogens
should be also performed utilizing routine laboratory procedures
(189). Currently, two types of diagnostic kits for SARS-CoV-2
are available: genomic (RNA-based, long, precise) and serologi-
cal (IgM/IgG-based; fast, relatively imprecise).
Nucleic acid amplification test (NAAT)
The WHO recommends a RT-PCR test for SARS-CoV-2
detection (185, 189); RT-PCR was the first established and
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rapidly commercialized diagnostic method in the SARS-CoV-2
pandemic (191, 192). The WHO testing recommendations
differ depending on the SARS-CoV-2 prevalence. In the
virus-free areas, a positive NAAT for at least two target
SARS-CoV-2 genes is considered reliable; in areas with
SARS-CoV-2 presence, a confirmation of a single discrimina-
tory target is sufficient (185, 189). The Chinese National
Institute for Viral Disease Control and Prevention recommends
a cycle threshold value (Ct-value) below 37 as positive, Ct-
value >40 as negative test (193), and (40) <Ct-value< 40
requiring retesting. The intermediate values have frequently
been associated with reported false-negative rates (194). There-
fore, a negative RT-PCR result does not necessarily rule out the
possibility of SARS-CoV-2 infection (194). The WHO quotes
several culprit factors including a poor specimen quality, timing
of specimen collection, specimen handling, and/or shipping
and various technical problems (189). A small Chinese study
demonstrated that some COVID-19 patients who met criteria
for hospital discharge and/or quarantine discontinuation (free
of clinical symptoms, radiological abnormalities and with two
negative RT-PCR tests) were tested positive (by RT-PCR) 5 to
13 days later (195). A South Korean study reported that two out
of 10 negative COVID-19 cases by RT-PCR were later con-
firmed as positive (196). In a large study, the second RT-PCR
test was positive in 12.5% of initially negative 384 patients
(197). Thus, the detection of SARS-CoV-2 is highly specific
(no false positives) but the sensitivity is not ideal (198). These
findings reveal limitations of RT-PCR testing and indicate that
some recovered patients may continue to be virus carriers
(195). This phenomenon, if confirmed on a larger scale, may
force changes in the current criteria for hospital discharge and
quarantine discontinuation. Furthermore, the SARS-CoV-2
diagnostics should account for clinical findings; preliminary
data from China showed that isolated patients (with presumed
COVID-19) with initially negative RT-PCR but with typical
clinical and radiological COVID-19 symptoms were confirmed
as SARS-CoV-2-positive after repeated swab testing (194).
Thus, a combination of repeated RT-PCR testing and radiolog-
ical imaging may be helpful in determining suspected false-
negative cases.
Although the RT-PCR constitutes the current diagnostic
standard, the test kits suffer considerable limitations. In 610
patients, in the first all-patient test, 27.5% cases were positive,
0.2% weakly positive, 9.3% dubious, and 63% were negative
(197). Among the patients with initial negative results, the
second test was positive in 12.5%, dubious in 7% patients,
negative in 73% patients, and results were not available for
7.6% patients (197). The false-negative readouts are also
contingent on the workflow for molecular detection (e.g.,
and isolation method with/without commercial kit) (194,
195, 199). Additionally, RT-PCR has long turnaround times,
requires certified laboratories, expensive equipment, and
trained personnel. Due to these limitations, RT-PCR may not
be practical as a rapid and simple diagnostic and/or screening
tool. There is an urgent need for a fast, sensitive, accurate, and
simple test to process a large number of suspected and asymp-
tomatic carriers. Moreover, there is a pressing need for rapid,
digital analyses of viral load as the field moves forward.
Serological testing
Serologic detection of specific IgM/IgG antibodies consti-
tutes a rapid, simple, and cost-effective complementation to
NAAT (170). The WHO continues to evaluate and update all
available immunodiagnostic tests for COVID-19 (200). One of
the newest point-of-care tools is the lateral flow immunoassay
test able to detect IgM and IgG in the blood sample within
15 min (201). Since the IgG concentration begins to rise as IgM
levels start to drop, the dynamic pattern in COVID-19 patients
is consistent with an acute viral infection (202).
The serological SARS-CoV-2 testing with an average sensi-
tivity of 88.7% and a specificity of 90.6% faces the risks of both
false-positive and false-negative readouts (201). The key test-
ing limitations include low antibody concentrations, differ-
ences in individual immune responses and antibody
production, and quick changes in the IgM/IgG ratio (201);
possible cross-reactivity with other corona and flu viruses
cannot be excluded (203, 204). The above shortcomings prac-
tically preclude defining the exact infection time-point and the
length of infection. Over 500 commercial SARS-CoV-2 tests
are currently available or under development ((205); https://
www.finddx.org/covid-19/pipeline/); however, their efficacy
remains limited and the validation of their clinical performance
and quality constitutes a global priority (200). As of April 8,
2020, the WHO does not recommend the use of antibody-
detecting rapid diagnostic tests for direct patient assessment;
their application is encouraged for COVID-19 surveillance and
epidemiological research (200).
MODELING AND TRANSLATIONAL TECHNOLOGY
FOR MONITORING AND THERAPEUTIC
STRATEGIES
The knowledge gaps in our understanding of COVID-19
pathophysiology and the complexity of treatment validation are
major limitations for the current standard of care. One possible
strategy to overcome this is to engage complex statistical and
physiological modeling. In silico models devoted to big data
analysis and encompassing systems biology and precision
medicine concepts have been introduced to inflammation,
trauma, and sepsis research as a new complementary tool
supporting translational applications (206–208). Similarly,
advanced data analysis techniques constitute a potential support
in the interpretation of different clinical COVID-19 presenta-
tions, in the timely identification of infected subjects prone to
ARDS, and in the prediction of patient trajectories and their
complication risks while on the ICU.
Artificial intelligence (AI) has been already introduced into
the fight against SARS-CoV-2 (209). Despite the poor quality
and inhomogeneity of the available data (that affect the model-
ing robustness and accuracy), AI may hold potential for the
prediction and monitoring of SARS-CoV-2 outbreak hot-spots,
transmission, and spread. For example, the analysis of big data
from the commercial aviation industry was used to predict
patterns of the international SARS-CoV-2 spread (210). Given
the suboptimally coordinated response to the original outbreak,
it is advisable that transnational organizations such as the WHO
as well as national governments and local health systems
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integrate AI-based analyses to support their decision-making
in: the design and implementation of lockdown and post-
lockdown strategies and the early identification and prevention
of second infection waves. Such applications have already been
proposed to predict the preparedness and vulnerability to
SARS-CoV-2 in Africa (211) and could be expanded to other
continents/regions around the globe. Artificial intelligence can
be also used in a cluster fashion in individual clinics. For
example, AI-powered automated analysis of chest X-rays and
CT scans effectively reduced the workload of radiologists
(212–215); AI identified COVID-19-induced airway injury
and pneumonia of varying magnitude as accurately as human
operators. Thus, AI applications appear as a time- and resource-
saving alternative in diagnosing COVID-19 in mildly symp-
tomatic individuals. Recently, a multidisciplinary global initia-
tive to leverage AI in the fight against COVID-19 was launched
in Belgium together with hospitals and organizations world-
wide (icometrix/icolung, Leuven (Belgium), Chicago). This
multinational collaboration resulted in the development of an
AI solution for rapid and objective quantification of lung
pathology on chest CT scans in admitted COVID-19 patients
(Fig. 5).
Despite its epidemiological and diagnostic potential, it is
premature to expect AI to be a game-changer in real-time
patient monitoring (216). It is unclear whether AI can precisely
prognosticate, and its usefulness has been modest in the context
of therapy design. Even though AI algorithms have been used to
predict the efficacy of existing drugs repurposed to treat
COVID-19 (217, 218), the candidate drugs (and pharmacolog-
ical targets) still require experimental validation before trans-
lating them to bedside and into clinical practice. Interestingly,
promising results were obtained from the analysis of high-
throughput data on the interaction between SARS-CoV-2 and
ACE2 receptors encouraging research on interventions prevent-
ing the internalization of SARS-CoV-2 (131, 219).
The contribution of data-driven models in the improvement
of patient monitoring and in the design of new therapeutic
approaches critically depends on the quality of the available
FIG. 5. Example of a fully automated assessment of the total and lobar disease burden in COVID-19 pneumonia based upon an AI algorithm.
Evaluating the type, pattern, and extent of lung pathology on chest CT can help in the assessment, triage, and follow-up of COVID-19 patients. (Source: Jan
Verheyden, icometrix (icolung), Leuven, Belgium). COVID-19 indicates coronavirus disease 2019; CT, computed tomography; AI, artificial intelligence.
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data; it is key to ensure the best possible consistency and
homogeneity across databases. Initiatives such as the
COVID-19 data portal by the European Molecular Biology
Laboratory—European Bioinformatics Institute (EMBL-EBI)
(https://www.covid19dataportal.org/about) and the CORD-19
(COVID-19 Open Research Dataset) by the Allen Institute for
AI (Seattle, Wash) and collaborators (https://allenai.org/data/
cord-19) exemplify this paradigm and support the development
of knowledge-based models to formulate and test hypotheses
on the desired pathological mechanisms of interest, and char-
acterize and interpret the dynamics of the disease progression in
real time. Physiological models will likely benefit from the
integration of data from different levels of the biological scale.
In particular, high-throughput, multi-omics data have been
increasingly used in acute illness (220–226) to investigate
disease pathways and their molecular signatures, and to search
for novel diagnostic biomarkers and therapeutic targets. The
use of multiscale models in COVID-19 research could shed
light on the complexity of phenotypes and enhance the design
of combinatorial treatments not limited to a single drug or
intervention. A recent study (227) used a multi-omic approach
and machine learning algorithms to analyze COVID-19 sig-
natures; the data showed that COVID-19 severity was associ-
ated with distinct profiles in the serum proteome and
metabolome, implicating massive metabolic suppression, mac-
rophage dysregulation, platelet degranulation, and complement
system imbalance. Multilevel data integration, including the -
omics, hemodynamic, biochemical, and clinical readouts,
could further advance our understanding of the relationships
among various COVID-19 phenotypes such as bilateral pneu-
monia/ARDS requiring mechanical ventilation (228), shock
requiring vasopressor support (229, 230), cardiomyopathy
(231), and neurological manifestations (232).
Retrospective studies will be necessary to build and validate
physiological multiscale models. The success of this effort will
rely on the availability of well-annotated, cohesive, and con-
sistent databases and corresponding biobanks. The integration
of statistical (data-driven) modeling and physiological (knowl-
edge-based) modeling should be pursued to enhance the trans-
lational potential of computational analytics for: diagnostics
and monitoring, the design of novel, more effective treatments,
the guidance of therapy by decision support systems.
DISSEMINATION OF DATA AND LARGE-SCALE
TRANSLATIONAL RESEARCH NETWORKS
The SARS-CoV-2 outbreak has triggered an unprecedented
cooperative activity worldwide, yet with varying perception and
outcomes. Major funding agencies including the European
Commission with dedicated emergency funding action under
the Horizon 2020 Framework Program, the National Institutes of
Health and other funding agencies such as the Department of
Defense among others, and numerous national agencies have
mobilized funds to facilitate rapid basic and clinical research on
the SARS-CoV-2 pathogenesis and COVID-19 treatments.
While this greatly supports COVID-19-oriented research, it
simultaneously puts other important research areas at risk of
slowdown and under-funding. To enable an uninhibited and rapid
exchange of emerging knowledge, major publishers such as
Elsevier (https://www.elsevier.com/connect/coronavirus-infor-
mation-center), Springer Nature (https://www.springernature.
com/gp/researchers/campaigns/coronavirus) JAMA, (https://
ja.ma/covidyt), The Lancet, The New England Journal of Medi-
cine, and Science, among others, have gone open-access cover-
ing multiple SARS-CoV-2/COVID-19-related topics. The video/
audio knowledge exchange has been at its finest; the JAMA
Update podcast with Dr. M Cecconi (March 3, 2020) from the
Italian COVID-19 frontline was followed by over million view-
ers (233) and the 7 h-long COVID-19 Marathon Webinar orga-
nized by ESICM (March 23, 2020) gathered expert-speakers
from 15 countries and four continents (https://esicm-tv.org/
covid19/). However, perception of the rapid data dissemination
by the preprint servers (e.g., bioRxiv.org; medRxiv.org) is less
favorable. There has been a growing concern that such a steep
growth of unscrutinized scientific evidence (3718 bio/medRxi-
v.org articles on SARS-CoV-2/COVID-19; accessed May 19,
2020) rather provokes more confusion than meritorious guidance
and indiscriminately selected pieces of the preprinted data are
recurrently sensationalized by the lay press.
While the majority of above activities are effective (and
impressive), there is an important gap: the lack of a functional
translational-research collaborative network on the SARS-
CoV-2/COVID-19 pandemic. Although clinical studies are
costly and organizationally challenging, clinical centers can
join them with relative ease and without a need for additional
and/or specialized core facilities. This is in sharp contrast to
basic and translational studies. While the progress in modern
basic science can be made using online resources like sequenc-
ing and structural data, e.g., enabling in silico modeling (234),
translational studies require work with live SARS viruses and
animal models at biosafety level (BSL)-3 facilities (https://
www.cdc.gov/sars/guidance/f-lab/app5.html). The availability
of SARS-CoV-2-susceptible animals and BSL-3 labs is limited.
Therefore, efforts should be undertaken to enhance cooperation
among existing centers by creating international collaborative
research platforms able to simultaneously investigate multiple
hypotheses/aims. This can be achieved by implementing three
key objectives: to galvanize an open-access scientific exchange
and tools (e.g., models, protocols) among laboratories, to
facilitate a multilateral data flow among basic science research-
ers in an organized, standardized fashion, and to improve the
validity of preclinical treatment studies by introduction of
multicenter animal testing. Encouraging examples of such
strategies exist; beginning with China (2020/01/21), hCoV-
19 genome sequences have been rapidly and freely shared
by the international scientific community (virological.org;
GenBank; www.gisaid.org/), some SARS-CoV-2-related find-
ings are published patent-free (235) and first multicenter ani-
mal studies have shown a superior reproducibility and validity
(236). A few of such preclinical collaborative networks have
also been found in the area of critical care medicine; Operation
Brain Trauma Therapy is a fully operational US-based multi-
center drug and biomarker screening consortium for traumatic
brain injury (237), whereas the international Wiggers-Bernard
Initiative is in the process of forming a multicenter preclinical
RCT in mouse sepsis (https://wiggers-bernard.org/2019-topic/).
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In the context of COVID-19, especially the trials performed in
non-human primates would highly benefit from a multicenter
coordinated approach given that single-center studies are typi-
cally limited to very low numbers (n¼ 4–6) of animals (120,
238, 239). The translational research community should also
learn from the clinical examples that employ additional, more
advanced designs: for example, the REMAP-CAP trial enables
multicenter large-scale and adaptive-design treatment testing.
Adaptation and utilization of the above strategies in preclinical
research will likely save time and resources, increase rigor of the
findings, and enhance the bidirectional flow of data between the
laboratories and clinic (and vice versa) given their tighter
alignment.
Another key element is to strengthen regulatory partnerships
among institutions and countries that would directly comple-
ment large-scale multicenter preclinical and clinical studies,
through initiatives such as creation of shared data repositories
and associated biobanks with patient or animal samples for
future retrospective studies. A Dutch-based (private-govern-
ment-academic) Molecular Diagnosis and Risk Stratification of
Sepsis consortium (https://consortiapedia.fastercures.org/con-
sortia/mars/) exemplifies such an approach; organized in four
complementary working packages brings together several inter-
national partners and integrates clinical, discovery, and tech-
nology data-sharing platforms. Similarly, the largest existing
military registry for combat-related trauma patients (with data
on combat casualty care epidemiology, treatments, and longi-
tudinal outcomes) has been created by the US Department of
Defense Joint Trauma System (https://jts.amedd.army.mil/). On
April 20, 2020 the European Commission, in cooperation with
the EMBL-EBI, deployed a data platform specifically dedi-
cated to COVID-19 to collect and share scientific evidence
(https://www.covid19dataportal.org). The availability of
diverse data types from different clinical centers can enhance
the validation of both data-driven and knowledge-based mod-
els, leading to a faster introduction of diagnostic and patient
monitoring tools as well as decision support systems.
CONCLUSIONS
COVID-19 represents a major global health challenge for the
up-coming months and years. SARS-CoV-2 infection likely
presents in various phenotypes reflected by differential immu-
nopathogenesis. While many derangements contribute to the
pathophysiology of COVID-19, particularly damage to the
endothelium along with altered hemostasis appear to be
the key driver and link between the different phenotypes.
Despite many similarities, the SARS-CoV2/COVID-19 is not
identical to MERS and SARS-CoVand should be contemplated
as a novel and independent disease entity. Reliable scientific
evidence regarding SARS-CoV-2/COVID-19 epidemiology,
infectivity, host response, as well as clinical assessment and
treatments needs to be generated through a verified, orches-
trated, large-scale transnational, and interdisciplinary effort
rather than anecdotal, idiosyncratic preclinical studies and
multiple small-scale, low-powered clinical trials. It is impera-
tive that the currently contemplated therapeutic strategies
adhere to the theranostic-like principle to avoid the past failed
treatments that indiscriminately targeted heterogenous patients
(with sepsis as an example). Consensus-based ‘‘Master Proto-
cols’’ for data reporting and clinical trials constitute the basis
for uniform contingency protocols, rapid and coordinated
implementation of emergency measures, and reliable evalua-
tion of therapeutics and vaccines. Advanced data analysis
techniques can help in the interpretation of different clinical
COVID-19 presentations, rapid risk stratification, and pre-
diction of outcomes. In the absence of approved drugs to
prevent and/or treat COVID-19, the magnitude of the current
pandemia may justify extraordinary measures to save patient
lives but these have to be balanced against ethical and
scientific safeguards. Any review of an ongoing pandemic
is highly fluid and the dynamic nature of the research on the
disease, its progression and our understanding of its epide-
miology and pathogenesis may already be partly outdated on
the day of publication. Thus, the complete, hopefully inspir-
ing, story of the SARS-CoV-2/COVID-19 pandemic will be
written in years from now.
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